doi: 10.1001/jamainternmed.2013.2720 61 NoelRABraunDKPattersonREBloomgrenGL
Stomach Pain on Reta vs Other GLP-1 Compounds Cross-trial comparisons have significant limitations, but directional data helps contextualize the stomach pain experience on retatrutide: Metric Retatrutide 12 mg Semaglutide 2.4 mg Tirzepatide 15 mg Overall GI events ~67% ~74% ~51% Nausea ~46% ~44% ~31% Diarrhea ~33% ~30% ~23% Vomiting ~22% ~24% ~12% Discontinuation due to GI AEs ~8% ~7% ~6% Key observation: Despite targeting three receptors instead of one or two, retatrutide's overall GI adverse event rate is comparable to semaglutide and modestly higher than tirzepatide
Contact your healthcare provider if fatigue is persistent, severe, or worsening, as it may indicate underlying issues such as anemia, thyroid dysfunction, vitamin deficiencies, or inadequate glycemic control
It's also frequently misrepresented - used to make promises about compounded products that the original trials don't support
They want a medically grounded plan that helps them lose fat while protecting function, energy, and long-term results
Please consult your healthcare provider for personalized medical advice.
